Quinnova Pharmaceuticals wins FDA clearance for Neosalus Cream

Quinnova Pharmaceuticals, a specialty pharmaceutical company, has received the FDA clearance for the company’s new product Neosalus Cream, a line extension to the previously launched Neosalus Foam, the first non-steroidal anti-inflammatory prescription topical foam product for the treatment of various types of dermatoses including atopic dermatitis and hand eczema.

Both Neosalus Cream and Neosalus Foam are said to be uniquely formulated with Quinnova’s patented Proderm Technology, which provides skin barrier repair, protection, and moisturization.

In addition to the therapeutic benefits of Neosalus Cream and Neosalus Foam, patients will likely appreciate the cosmetic elegance of Proderm Technology. Unlike some creams and lotions which have a tendency to leave the skin feeling greasy after application, Neosalus, a water-lipid based formulation, absorbs quickly, spreads easily, and is non-greasy, the company said.

Christopher Hensby, senior vice president of Quinnova, said: To treat recalcitrant skin conditions such as atopic dermatitis and hand eczema, a comprehensive and long term solution is required to address the underlying issue of a compromised skin barrier while reducing inflammation.

Neosalus Cream, in addition to Neosalus Foam, increases the product selection choice of Quinnova’s Neosalus brand for both the patient and the healthcare provider.